Underdetection of laboratory-confirmed influenza-associated hospital admissions among infants: a multicentre, prospective study.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
11 2019
Historique:
received: 23 05 2019
revised: 09 07 2019
accepted: 10 07 2019
pubmed: 8 9 2019
medline: 27 5 2020
entrez: 8 9 2019
Statut: ppublish

Résumé

Since influenza often presents non-specifically in infancy, we aimed to assess the extent to which existing respiratory surveillance platforms might underestimate the frequency of severe influenza disease among infants. The Influenza and Respiratory Syncytial Virus in Infants (IRIS) study was a prospective observational study done at four hospitals in Albania, Jordan, Nicaragua, and the Philippines. We included acutely ill infants aged younger than 1 year admitted to hospital within 10 days or less of illness onset during two influenza seasons (2015-16 and 2016-17) in Albania, Jordan, and Nicaragua, and over a continuous 34 week period (2015-16) in the Philippines. We assessed the frequency of influenza virus infections by real-time RT-PCR (rRT-PCR) and serology. The main study outcome was seroconversion, defined as convalescent antibody titres more than or equal to four-fold higher than acute sera antibody titres, and convalescent antibody titres of 40 or higher. Seroconverison was confirmed by haemagglutination inhibition assay for influenza A viruses, and by hemagglutination inhibition assay and microneutralisation for influenza B viruses. Between June 27, 2015, and April 21, 2017, 3634 acutely ill infants were enrolled, of whom 1943 were enrolled during influenza seasons and had complete acute-convalescent pairs and thus were included in the final analytical sample. Of the 1943 infants, 94 (5%) were influenza-positive by both rRT-PCR and serology, 58 (3%) were positive by rRT-PCR-only, and 102 (5%) were positive by serology only. Seroconversion to at least one of the influenza A or B viruses was observed among 196 (77%) of 254 influenza-positive infants. Of the 254 infants with influenza virus, 84 (33%) only had non-respiratory clinical discharge diagnoses (eg, sepsis, febrile seizures, dehydration, or other non-respiratory viral illness). A focus on respiratory diagnoses and rRT-PCR-confirmed influenza underdetects influenza-associated hospital admissions among infants by a factor of 2·6 (95% CI 2·0-3·6). Findings were unchanged when syndromic severe acute respiratory infection criteria were applied instead of clinical diagnosis. If the true incidence of laboratory-confirmed influenza-associated hospital admissions among infants is at least twice that of previous estimates, this substantially increases the global burden of severe influenza and expands our estimates of the preventive value of maternal and infant influenza vaccination programmes. US Centers for Disease Control and Prevention.

Sections du résumé

BACKGROUND
Since influenza often presents non-specifically in infancy, we aimed to assess the extent to which existing respiratory surveillance platforms might underestimate the frequency of severe influenza disease among infants.
METHODS
The Influenza and Respiratory Syncytial Virus in Infants (IRIS) study was a prospective observational study done at four hospitals in Albania, Jordan, Nicaragua, and the Philippines. We included acutely ill infants aged younger than 1 year admitted to hospital within 10 days or less of illness onset during two influenza seasons (2015-16 and 2016-17) in Albania, Jordan, and Nicaragua, and over a continuous 34 week period (2015-16) in the Philippines. We assessed the frequency of influenza virus infections by real-time RT-PCR (rRT-PCR) and serology. The main study outcome was seroconversion, defined as convalescent antibody titres more than or equal to four-fold higher than acute sera antibody titres, and convalescent antibody titres of 40 or higher. Seroconverison was confirmed by haemagglutination inhibition assay for influenza A viruses, and by hemagglutination inhibition assay and microneutralisation for influenza B viruses.
FINDINGS
Between June 27, 2015, and April 21, 2017, 3634 acutely ill infants were enrolled, of whom 1943 were enrolled during influenza seasons and had complete acute-convalescent pairs and thus were included in the final analytical sample. Of the 1943 infants, 94 (5%) were influenza-positive by both rRT-PCR and serology, 58 (3%) were positive by rRT-PCR-only, and 102 (5%) were positive by serology only. Seroconversion to at least one of the influenza A or B viruses was observed among 196 (77%) of 254 influenza-positive infants. Of the 254 infants with influenza virus, 84 (33%) only had non-respiratory clinical discharge diagnoses (eg, sepsis, febrile seizures, dehydration, or other non-respiratory viral illness). A focus on respiratory diagnoses and rRT-PCR-confirmed influenza underdetects influenza-associated hospital admissions among infants by a factor of 2·6 (95% CI 2·0-3·6). Findings were unchanged when syndromic severe acute respiratory infection criteria were applied instead of clinical diagnosis.
INTERPRETATION
If the true incidence of laboratory-confirmed influenza-associated hospital admissions among infants is at least twice that of previous estimates, this substantially increases the global burden of severe influenza and expands our estimates of the preventive value of maternal and infant influenza vaccination programmes.
FUNDING
US Centers for Disease Control and Prevention.

Identifiants

pubmed: 31492594
pii: S2352-4642(19)30246-9
doi: 10.1016/S2352-4642(19)30246-9
pmc: PMC7029431
mid: NIHMS1069109
pii:
doi:

Substances chimiques

Antibodies, Viral 0
DNA, Viral 0

Types de publication

Journal Article Multicenter Study Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

781-794

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

J Glob Health. 2015 Jun;5(1):010408
pubmed: 26445672
Clin Vaccine Immunol. 2013 Jan;20(1):113-4
pubmed: 23114699
Paediatr Respir Rev. 2003 Jun;4(2):99-104
pubmed: 12758046
JAMA Pediatr. 2015 Sep;169(9):846-54
pubmed: 26192102
Expert Rev Respir Med. 2011 Aug;5(4):459-63
pubmed: 21859263
Vaccine. 2007 May 10;25(19):3827-33
pubmed: 17367898
J Hosp Infect. 2003 Oct;55(2):83-91
pubmed: 14529631
BMC Infect Dis. 2017 Mar 22;17(1):222
pubmed: 28330443
Clin Infect Dis. 2012 Feb 1;54(3):445-6
pubmed: 22057703
Pediatr Infect Dis J. 2007 Feb;26(2):142-7
pubmed: 17259877
Influenza Other Respir Viruses. 2011 Jul;5(4):288-95
pubmed: 21651740
Pediatr Infect Dis J. 2014 Sep;33(9):912-9
pubmed: 24577042
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
Vaccine. 2017 Oct 13;35(43):5738-5750
pubmed: 28867508
J Infect. 2015 Feb;70(2):160-70
pubmed: 25218056
Vaccine. 2013 Nov 4;31(46):5339-48
pubmed: 24055351
Trends Immunol. 2014 Jul;35(7):299-310
pubmed: 24880460
Lancet. 2011 Dec 3;378(9807):1917-30
pubmed: 22078723
BMC Infect Dis. 2015 Oct 24;15:447
pubmed: 26497393
J Clin Microbiol. 2013 Nov;51(11):3880-2
pubmed: 24108606
Lancet Infect Dis. 2011 Mar;11(3):223-35
pubmed: 21371656
J Infect Dis. 2019 Jan 7;219(2):197-205
pubmed: 30189092
Vaccine. 2016 Jun 24;34(30):3443-6
pubmed: 27195761
MMWR Recomm Rep. 2018 Aug 24;67(3):1-20
pubmed: 30141464
Pediatrics. 2004 Mar;113(3 Pt 1):585-93
pubmed: 14993554
PLoS One. 2015 Mar 04;10(3):e0118369
pubmed: 25738736
Vaccine. 2018 Sep 5;36(37):5524-5535
pubmed: 30078745
Pediatr Infect Dis J. 2011 Feb;30(2):e24-8
pubmed: 21298851
Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83
pubmed: 21692672
Vaccine. 2018 Jun 14;36(25):3686-3693
pubmed: 29748029
Pediatr Infect Dis J. 2003 Oct;22(10 Suppl):S218-22
pubmed: 14551479
Expert Rev Vaccines. 2013 May;12(5):519-36
pubmed: 23659300
Vaccine. 2016 Jan 2;34(1):20-32
pubmed: 26602267

Auteurs

Mark G Thompson (MG)

Influenza Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: isq8@cdc.gov.

Min Z Levine (MZ)

Influenza Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Silvia Bino (S)

Department of Epidemiology and Control of Infectious Diseases, Institute of Public Health, Tirana, Albania.

Danielle R Hunt (DR)

Abt Associates, Atlanta, GA, USA.

Tareq M Al-Sanouri (TM)

The Eastern Mediterranean Public Health Network (EMPHNET), Amman, Jordan.

Eric A F Simões (EAF)

Center for Global Health, Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA.

Rachael M Porter (RM)

Influenza Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Holly M Biggs (HM)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lionel Gresh (L)

Sustainable Sciences Institute, Managua, Nicaragua.

Artan Simaku (A)

Department of Epidemiology and Control of Infectious Diseases, Institute of Public Health, Tirana, Albania.

Illham Abu Khader (IA)

The Eastern Mediterranean Public Health Network (EMPHNET), Amman, Jordan.

Veronica L Tallo (VL)

Research Institute for Tropical Medicine, Department of Health, Muntinlupa, Philippines.

Jennifer K Meece (JK)

Marshfield Clinic Research Foundation, Marshfield, WI, USA.

Meredith McMorrow (M)

Influenza Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Edelwisa S Mercado (ES)

Research Institute for Tropical Medicine, Department of Health, Muntinlupa, Philippines.

Sneha Joshi (S)

Influenza Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Nicholas P DeGroote (NP)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Iris Hatibi (I)

Department of Epidemiology and Control of Infectious Diseases, Institute of Public Health, Tirana, Albania.

Felix Sanchez (F)

Hospital Infantil Manuel de Jesus Rivera, Ministry of Health, Managua, Nicaragua.

Marilla G Lucero (MG)

Research Institute for Tropical Medicine, Department of Health, Muntinlupa, Philippines.

Samir Faouri (S)

Al Bashir Hospital, Ministry of Health, Amman, Jordan.

Stacie N Jefferson (SN)

Influenza Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Numila Maliqari (N)

General Pediatrics Unit, University Hospital Center "Mother Teresa", Tirana, Albania.

Angel Balmaseda (A)

Laboratorio Nacional de Virologia, Centro Nacional de Diagnostico y Referencia, Ministry of Health, Managua, Nicaragua.

Diozele Sanvictores (D)

Research Institute for Tropical Medicine, Department of Health, Muntinlupa, Philippines.

Crystal Holiday (C)

Influenza Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Cristina Sciuto (C)

Abt Associates, Atlanta, GA, USA.

Zachary Owens (Z)

Influenza Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Eduardo Azziz-Baumgartner (E)

Influenza Division, National Center for Immunization and Respiratory Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Aubree Gordon (A)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH